Related Experiment Video

Updated: Dec 23, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.5K

Use of sacubitril/valsartan in non-compaction cardiomyopathy: a case report

Marcely Gimenes Bonatto1,2, Rodrigo Albanez1, Vera Maria Cury Salemi3

  • 1Department of Cardiology, Heart Failure and Heart Transplantation Section of Santa Casa de Misericórdia Hospital, Curitiba, Paraná, Brazil.

ESC Heart Failure
|April 19, 2020
PubMed

Insights

Sacubitril/valsartan improved heart failure symptoms and ejection fraction in a patient with non-compaction cardiomyopathy (NCCM) refractory to standard treatments. This suggests potential benefits of sacubitril/valsartan for NCCM patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Non-compaction cardiomyopathy (NCCM) is a rare congenital heart defect.
  • Standard treatments for heart failure in NCCM often show limited efficacy.
  • Sacubitril/valsartan is a proven therapy for heart failure with reduced ejection fraction.

Observation:

  • A 48-year-old woman with NCCM heart failure was refractory to 18 months of guideline-directed medical therapy.
  • Sacubitril/valsartan was initiated due to the lack of treatment response.

Findings:

  • The patient showed significant improvement in functional class from III to I.
  • Ejection fraction increased by 29%, ventricular diastolic diameter reduced by 7 mm.
  • Mitral valve regurgitation improved to mild or none.

Implications:

  • Sacubitril/valsartan may be a viable treatment option for NCCM patients with heart failure.
  • Further studies are warranted to confirm these findings in a larger NCCM population.
  • This case highlights the potential of sacubitril/valsartan in managing refractory heart failure in rare cardiomyopathies.

Keywords:
Heart failureReverse remodellingSacubitril/valsartannon-compaction cardiomyopathy

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.8K

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
339
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
228
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
811
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
365
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
282
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
159